Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila… - Proceedings of the …, 2012 - National Acad Sciences
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
K Ohashi, LV Sequist, ME Arcila, T Moran… - Proceedings of the …, 2012 - europepmc.org
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila… - … of the National …, 2012 - mdanderson.elsevierpure.com
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
[HTML][HTML] Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila, T Moran… - Proceedings of the …, 2012 - ncbi.nlm.nih.gov
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila, T Moran… - Proceedings of the …, 2012 - cir.nii.ac.jp
抄録< jats: p> Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs)
is inevitable in metastatic< jats: italic> EGFR</jats: italic>-mutant lung cancers. Here, we …
is inevitable in metastatic< jats: italic> EGFR</jats: italic>-mutant lung cancers. Here, we …
[引用][C] Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, T Moran, J Chmielecki… - Proceedings of the …, 2012 - pure.mpg.de
PNAS Plus: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila… - Proceedings of the …, 2012 - ui.adsabs.harvard.edu
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila… - Proceedings of the …, 2012 - portalrecerca.uab.cat
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
[PDF][PDF] Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashia, LV Sequistb, ME Arcilad, T Morane… - researchgate.net
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR …
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila… - … of the National …, 2012 - okayama.elsevierpure.com
抄録 Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is
inevitable in metastatic EGFR-mutant lung cancers. Here, we modeled disease progression …
inevitable in metastatic EGFR-mutant lung cancers. Here, we modeled disease progression …